However, there is no general consensus as to whether and how GSK-3β activity is altered in AD patients (Blalock et al., 2004; Hye et al., 2005; Leroy et al., 2007; Pei et al., 1997; Swatton et al., 2004). This evidence concerns the gene GSK3B and Alzheimer disease.